Drug-eluting stent safety: Findings from preclinical studies

Expert Review of Cardiovascular Therapy

Volumn 6, Issue 10, 2008, Pages 1379-1391

  Nakazawa, Gaku ^a   Finn, Aloke V ^b   Ladich, Elena ^a   Ribichini, Flavio ^c   Coleman, Leslie ^d   Kolodgie, Frank D ^a   Virmani, Renu ^a  

^a CVPATH INSTITUTE   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF VERONA   (Italy)

^d ABBOTT VASCULAR   (United States)

Author keywords

Drug eluting stent; Porcine model; Preclinical study; Rabbit model

Indexed keywords

EVEROLIMUS; PACLITAXEL; POLY(N BUTYL)METHACRYLATE; POLY(STYRENE B ISOBUTYLENE B STYRENE); POLYETHYLENE VINYL ACETATE COPOLYMER; POLYMER; PREDNISONE; RAPAMYCIN; UNCLASSIFIED DRUG; ZOTAROLIMUS;

ARTERIAL WALL THICKNESS; ARTERY INJURY; ATHEROSCLEROSIS; BARE METAL STENT; CORONARY ARTERY DISEASE; DRUG DELIVERY SYSTEM; DRUG ELUTING STENT; EXPERIMENTAL ANIMAL; HISTOPATHOLOGY; IN-STENT RESTENOSIS; INFLAMMATION; LONG TERM CARE; MATERIAL COATING; NONHUMAN; RABBIT; REVIEW; RISK ASSESSMENT; SAFETY; SWINE; ACUTE CORONARY SYNDROME; ANIMAL; DISEASE MODEL; DRUG SCREENING; ENDOTHELIUM CELL; FOOD AND DRUG ADMINISTRATION; HUMAN; METABOLISM; METHODOLOGY; SPECIES DIFFERENCE; THROMBOSIS; TIME; UNITED STATES;

ACUTE CORONARY SYNDROME; ANIMALS; ATHEROSCLEROSIS; DISEASE MODELS, ANIMAL; DRUG EVALUATION, PRECLINICAL; DRUG-ELUTING STENTS; ENDOTHELIAL CELLS; HUMANS; RABBITS; SPECIES SPECIFICITY; SWINE; THROMBOSIS; TIME FACTORS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 59049099699     PISSN: 14779072     EISSN: 17448344     Source Type: Journal    
DOI: 10.1586/14779072.6.10.1379     Document Type: Review

References (47)

1. Morice MC, Serruys PW, Sousa JE et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N. Engl. J. Med. 346(23), 1773-1780 (2002).
2. Moses JW, Leon MB, Popma JJ et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N. Engl. J. Med. 349(14), 1315-1323 (2003).
3. Stone GW, Ellis SG, Cox DA et al. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N. Engl. J. Med. 350(3), 221-231 (2004).
4. Daemen J, Wenaweser P, Tsuchida K et al. Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study. Lancet 369(9562), 667-678 (2007).
5. Mauri L, Normand SL. Studies of drug-eluting stents: to each his own? Circulation 117(16), 2047-2050 (2008).
6. Ramcharitar S, Hochadel M, Gaster AL, Onuma Y, Gitt A, Serruys PW. An insight into the current use of drug eluting stents in acute and elective percutaneous coronary intervention in Europe; a report on the EuroPCI Survey. Eurointervention 3, 429-441 (2007).
7. Beohar N, Davidson CJ, Kip KE et al. Outcomes and complications associated with off-label and untested use of drug-eluting stems. JAMA 297(18), 1992-2000 (2007).
8. Farb A, Boam AB. Stent thrombosis redux - the FDA perspective. N. Engl. J. Med. 356(10), 984-987 (2007).
9. Win HK, Caldera AE, Maresh K et al. Clinical outcomes and stent thrombosis following off-label use of drug-eluting stents. JAMA 297(18), 2001-2009 (2007).
10. Marroquin OC, Selzer F, Mulukutla SR et al. A comparison of bare-metal and drug-eluting stents for off-label indications. N. Engl. J. Med. 358(4), 342-352 (2008).
11. Joner M, Finn AV, Farb A et al. Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. J. Am. Coll. Cardiol. 48(1), 193-202 (2006).
12. Finn AV, Joner M, Nakazawa G et al. Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization. Circulation 115(18), 2435-2441 (2007).
13. Virmani R, Kolodgie FD, Farb A, Lafont A. Drug eluting stents: are human and animal studies comparable? Heart 89(2), 133-138 (2003).
14. Clowes AW, Reidy MA, Clowes MM. Kinetics of cellular proliferation after arterial injury. I. Smooth muscle growth in the absence of endothelium. Lab Invest. 49(3), 327-333 (1983).
15. Zempo N, Koyama N, Kenagy RD, Lea HJ, Clowes AW. Regulation of vascular smooth muscle cell migration and proliferation in vitro and in injured rat arteries by a synthetic matrix metalloproteinase inhibitor. Arterioscler. Thromb. Vasc. Biol. 16(1), 28-33 (1996).
16. Sata M, Maejima Y, Adachi F et al. A mouse model of vascular injury that induces rapid onset of medial cell apoptosis followed by reproducible neointimal hyperplasia. J. Mol. Cell. Cardiol. 32(11), 2097-2104 (2000).
17. Lindner V, Reidy MA. Expression of VEGF receptors in arteries after endothelial injury and lack of increased endothelial regrowth in response to VEGF. Arterioscler. Thromb. Vasc. Biol. 16(11), 1399-1405 (1996).
18. Carter AJ, Aggarwal M, Kopia GA et al. Long-term effects of polymer-based, slow-release, sirolimus-eluting stents in a porcine coronary model. Cardiovasc. Res. 63(4), 617-624 (2004).
19. Kollum M, Kaiser S, Kinscherf R, Metz J, Kubler W, Hehrlein C. Apoptosis after stent implantation compared with balloon angioplasty in rabbits. Role of macrophages. Arterioscler. Thromb. Vasc. Biol. 17(11), 2383-2388 (1997).
20. Suzuki T, Kopia G, Hayashi S et al. Stent-based delivery of sirolimus reduces neointimal formation in a porcine coronary model. Circulation 104(10), 1188-1193 (2001).
21. Drachman DE, Edelman ER, Seifert P et al. Neointimal thickening after stent delivery of paclitaxel: change in composition and arrest of growth over six months. J. Am. Coll. Cardiol. 36(7), 2325-2332 (2000).
22. Aoki J, Abizaid AC, Serruys PW et al. Evaluation of four-year coronary artery response after sirolimus-eluting stent implantation using serial quantitative intravascular ultrasound and computer-assisted grayscale value analysis for plaque composition in event-free patients. J. Am. Coll. Cardiol. 46(9), 1670-1676 (2005).
23. Aoki J, Colombo A, Dudek D et al. Peristent remodeling and neointimal suppression 2 years after polymer-based, paclitaxel-eluting stent implantation: insights from serial intravascular ultrasound analysis in the TAXUS II study. Circulation 112(25), 3876-3883 (2005).
24. Morice MC, Serruys PW, Barragan P et al. Long-term clinical outcomes with sirolimus-eluting coronary stents: five-year results of the RAVEL trial. J. Am. Coll. Cardiol. 50(14), 1299-1304 (2007).
25. Garcia-Touchard A, Burke SE, Toner JL, Cromack K, Schwartz RS. Zotarolimus-eluting stents reduce experimental coronary artery neointimal hyperplasia after 4 weeks. Eur. Heart J. 27(8), 988-993 (2006).
26. Collingwood R, Gibson L, Sedlik S, Virmani R, Carter AJ. Stent-based delivery of ABT-578 via a phosphorylcholine surface coating reduces neointimal formation in the porcine coronary model. Catheter Cardiovasc. Interv. 65(2), 227-232 (2005).
27. Nakazawa G, Finn AV, John MC, Kolodgie FD, Virmani R. The significance of preclinical evaluation of sirolimus-, paclitaxel-, and zotarolimus-eluting stents. Am. J. Cardiol. 100(8B), 36M-44M (2007).
28. Ahmed DD, Sobczak SC, Yunginger JW. Occupational allergies caused by latex. Immunol. Allergy Clin. North Am. 23(2), 205-219 (2003).
29. Leggat PA, Kedjarune U. Toxicity of methyl methacrylate in dentistry. Int. Dent. J. 53(3) 126-131 (2003).
30. Wilson GJ, Nakazawa G, Schwartz RS et al. Comparison of inflammatory response following sirolimus and paclitaxel drug-eluting stents implanted in porcine coronary arteries, Circulation (2008) (In Press).
31. Edelman ER, Rogers C. Pathobiologic responses to stenting. Am. J. Cardiol. 81(7A), 4E-6E (1998).
32. Rogers C, Welt FG, Karnovsky MJ, Edelman ER. Monocyte recruitment and neointimal hyperplasia in rabbits. Coupled inhibitory effects of heparin. Arterioscler. Thromb. Vasc. Biol. 16(10), 1312-1318 (1996).
33. Farb A, Heller PF, Shroff S et al. Pathological analysis of local delivery of paclitaxel via a polymer-coated stent. Circulation 104(4), 473-479 (2001).
34. Heldman AW, Cheng L, Jenkins GM et al. Paclitaxel stent coating inhibits neointimal hyperplasia at 4 weeks in a porcine model of coronary restenosis. Circulation 103(18), 2289-2295 (2001).
35. Kolodgie FD, John M, Khurana C et al. Sustained reduction of in-stent neointimal growth with the use of a novel systemic nanoparticle paclitaxel. Circulation 106(10), 1195-1198 (2002).
36. Finn AV, Kolodgie FD, Harnek J et al. Differential response of delayed healing and persistent inflammation at sites of overlapping sirolimus- or paclitaxel-eluting stents. Circulation 112(2), 270-278 (2005).
37. Joner M, Nakazawa G, Finn AV et al. Endothelial cell recovery between comparator polymer-based drug-eluting stents. J. Am. Coll. Cardiol. 52(5), 333-342 (2008).
38. Rodgers GP, Minor ST, Robinson K et al. Adjuvant therapy for intracoronary stents. Investigations in atherosclerotic swine. Circulation 82(2), 560-569 (1990).
39. Virmani R, Kolodgie FD, Burke AP, Farb A, Schwartz SM. Lessons from sudden coronary death: a comprehensive morphological classification scheme for atherosclerotic lesions. Arterioscler. Thromb. Vasc. Biol. 20(5), 1262-1275 (2000).
40. Joner M, Farb A, Cheng Q et al. Pioglitazone inhibits in-stent restenosis in atherosclerotic rabbits by targeting transforming growth factor-β and MCP-1. Arterioscler. Thromb. Vasc. Biol. 27(1), 182-189 (2007).
41. Ribichini F, Joner M, Ferrero V et al. Effects of oral prednisone after stenting in a rabbit model of established atherosclerosis. J. Am. Coll. Cardiol. 50(2), 176-185 (2007).
42. Sakamoto J, Kimura H, Moriyama S et al. Activation of human peroxisome proliferator-activated receptor (PPAR) subtypes by pioglitazone. Biochem. Biophys. Res. Commun. 278(3), 704-711 (2000).
43. Kwak BR, Mulhaupt F, Mach F. The role of PPARγ ligands as regulators of the immune response. Drug News Perspect. 15(6), 325-332 (2002).
44. Law RE, Goetze S, Xi XP et al. Expression and function of PPARγ in rat and human vascular smooth muscle cells. Circulation 101(11), 1311-1318 (2000).
45. Schwartz RS, Edelman ER, Carter A et al. Drug-eluting stents in preclinical studies: recommended evaluation from a consensus group. Circulation 106(14), 1867-1873 (2002).
46. Finn AV, Nakazawa G, Joner M et al. Vascular responses to drug eluting stents: importance of delayed healing. Arterioscler. Thromb. Vasc. Biol. 27(7), 1500-1510 (2007).
47. Lüscher TF, Steffel J, Eberli FR et al. Drug-eluting stent and coronary thrombosis: biological mechanisms and clinical implications. Circulation 115(8), 1051-1058 (2007).